The exploration of Natural Killer (NK) cells in the context of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS, and multiple sclerosis is gaining traction in the scientific community. These cells, a component of the innate immune system, are known for identifying and reacting to infected or abnormal cells and influencing inflammatory responses through interactions with other immune cells. Despite the burgeoning interest, researchers caution that the clinical evidence supporting NK cell therapy as a viable treatment remains in its infancy, requiring further investigation.
In 2025, a Phase I clinical study shed some light on the potential of NK cells in treating Alzheimer’s disease. This study, which included 11 participants, focused on the safety of administering intravenously an autologous, non-genetically modified expanded NK cell product at intervals of three weeks. Researchers observed preliminary changes in cognitive measures and biomarkers related to neuroinflammation and neurodegeneration, notably pTau181 and GFAP, with no adverse events directly linked to the NK cell product. However, the study’s size and scope mean it was not conclusive enough to assert NK cell therapy’s efficacy in altering Alzheimer’s disease progression, necessitating larger and more comprehensive trials.
In the realm of Parkinson’s disease, preclinical studies have also generated interest. Research published in 2020 indicated that NK cells might play a pivotal role in managing neuroinflammation and alpha-synuclein aggregates, fundamental elements of Parkinson’s pathology. Experiments with mouse models revealed increased pathology when NK cells were depleted, suggesting their regulatory potential. Nonetheless, these findings remain primarily preclinical, and whether NK cell administration could serve as a therapeutic intervention in humans is yet to be determined.
The role of NK cells in neurological diseases is nuanced, with varying effects based on cell populations, disease stages, and tissue environments. Researchers are delving into which specific NK cell populations and treatment protocols might be most beneficial, as simply increasing NK cell numbers might not yield desired results. Critical questions regarding the cells’ impact on the central nervous system, patient suitability, and potential long-term effects of altering disease trajectories remain unanswered.
While NK cells are established players in immune surveillance and regulation, their application in treating neurodegenerative diseases is still under investigation. The promise seen in early laboratory and human studies requires further exploration to validate its effectiveness and safety. R3 Life Wellness Center emphasizes that individuals interested in cellular therapies should consult healthcare professionals and consider current scientific evidence and safety data. This article serves an educational purpose and does not constitute medical advice, stressing that NK cell therapy is not yet an established treatment for Alzheimer’s or Parkinson’s disease.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.